The 5-day half-life and weekly dosing schedule may improve medication adherence compared to daily injectable therapies, which is particularly valuable for patients with type 2 diabetes who often manage multiple medications
That opportunity is now supported by manufacturing commitments, including Novo Nordisk's March 2026 announcement of a EUR 432 million expansion in Athlone, Ireland, to increase capacity for oral GLP-1 therapies, alongside Eli Lilly's November 2025 plan to build a USD 3 billion manufacturing facility in Katwijk, the Netherlands, aimed at oral medicines including the GLP-1 receptor agonist orforglipron
Safety Profile: Whats New
If your skin barrier is already damaged from over-exfoliation, eczema flares, or aggressive treatment protocols, adding any new active, including GHK-Cu, can cause irritation